These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15833006)

  • 1. Drugs and the QT interval--implications for dentistry.
    Wynn RL
    Gen Dent; 2005; 53(2):94-7. PubMed ID: 15833006
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-induced prolongation of the QT interval.
    Roden DM
    N Engl J Med; 2004 Mar; 350(10):1013-22. PubMed ID: 14999113
    [No Abstract]   [Full Text] [Related]  

  • 3. Frequency of high-risk use of QT-prolonging medications.
    Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced prolongation of the QT interval.
    Cruciani RA; Portenoy RK; Homel P
    N Engl J Med; 2004 Jun; 350(25):2618-21; author reply 2618-21. PubMed ID: 15208786
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-induced prolongation of the QT interval.
    Curigliano G; Cipolla C; de Braud F
    N Engl J Med; 2004 Jun; 350(25):2618-21; author reply 2618-21. PubMed ID: 15208787
    [No Abstract]   [Full Text] [Related]  

  • 6. A farewell to QT dispersion. Are the alternatives any better?
    Rautaharju PM
    J Electrocardiol; 2005 Jan; 38(1):7-9. PubMed ID: 15660341
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-induced prolongation of the QT interval.
    Viskin S; Justo D; Zeltser D
    N Engl J Med; 2004 Jun; 350(25):2618-21; author reply 2618-21. PubMed ID: 15208785
    [No Abstract]   [Full Text] [Related]  

  • 8. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
    Hashimoto K
    Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL; Kung MF
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs and the QT interval - caveat doctor.
    Liu BA; Juurlink DN
    N Engl J Med; 2004 Sep; 351(11):1053-6. PubMed ID: 15356302
    [No Abstract]   [Full Text] [Related]  

  • 11. Early clinical development: evaluation of drug-induced torsades de pointes risk.
    Vik T; Pollard C; Sager P
    Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
    Tisdale JE; Kovacs R; Mi D; McCabe GP; Cariera BL; Sharma N; Rosman H
    Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes.
    Carlsson L
    Pharmacol Ther; 2008 Aug; 119(2):160-7. PubMed ID: 18558435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P; Hreiche R; Turgeon J
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
    Mok NS; Lo YK; Tsui PT; Lam CW
    J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient.
    Nair MK; Patel K; Starer PJ
    Addiction; 2008 Dec; 103(12):2062-4. PubMed ID: 19469750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced q-T prolongation.
    Kao LW; Furbee RB
    Med Clin North Am; 2005 Nov; 89(6):1125-44, x. PubMed ID: 16227057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for men and women - how important is gender as a risk factor for TdP?
    Coker SJ
    Pharmacol Ther; 2008 Aug; 119(2):186-94. PubMed ID: 18472167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged QT interval and torsades de pointes associated with atazanavir therapy.
    Ly T; Ruiz ME
    Clin Infect Dis; 2007 Mar; 44(6):e67-8. PubMed ID: 17304444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.